Intra-articular facet joint injections for low back pain: a systematic review

Rajni Vekaria¹ · Ree'thee Bhatt¹ · David R. Ellard² · Nicholas Henschke³ · Martin Underwood² · Harbinder Sandhu²

Received: 16 September 2015 / Revised: 30 January 2016 / Accepted: 31 January 2016 / Published online: 23 February 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

Purpose Evidence supporting the use of therapeutic intra-articular facet joint injections for patients with suspected facet joint pain is sparse. A systematic review including a narrative synthesis was carried out to determine if intra-articular facet joint injections with active drug are more effective in reducing back pain and back pain-related disability than a sham procedure or a placebo/inactive injection. Secondly, to determine if intra-articular facet joint injections with active drug or placebo/inactive

injection are more effective in reducing back pain and back pain-related disability than conservative treatment.

Methods Medline, EMBASE, CINAHL, CENTRAL, Index to Chiropractic Literature and the Cochrane Central Register of Controlled Trials were searched from inception through April 2015. Data were screened and single extraction with independent verification and risk of bias assessment was performed.

Results A total of 391 records were screened, and six trials were included. The trials included were small (range 18–109 participants) and overall in terms of pain and disability outcomes most were inconclusive. Only two of the trials report any significant between-group differences in pain (mean difference -1.0 , 95 % CI -2.0 to -0.1) and ($p = 0.032$) or disability (mean difference -3.0 , 95 % CI -6.2 to 0.2) and ($p = 0.013$) outcomes.

Conclusions The studies found here were clinically diverse and precluded any meta-analysis. A number of methodological issues were identified. The positive results, whilst interpreted with caution, do suggest that there is a need for further high-quality work in this area.

Keywords Systematic review · Intra-articular facet joint injections · Low back pain · Disability

Rajni Vekaria and Ree'thee Bhatt are joint first authors.

Electronic supplementary material The online version of this article (doi:10.1007/s00586-016-4455-y) contains supplementary material, which is available to authorized users.

✉ David R. Ellard
d.r.ellard@warwick.ac.uk

Rajni Vekaria
R.Vekaria@warwick.ac.uk

Ree'thee Bhatt
R-T.Bhatt@warwick.ac.uk

Nicholas Henschke
henschke@uni-heidelberg.de

Martin Underwood
m.underwood@warwick.ac.uk

Harbinder Sandhu
Harbinder.K.Sandhu@warwick.ac.uk

¹ Warwick Medical School, The University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK

² Warwick Clinical Trials Unit, The University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK

³ Institute for Public Health, University of Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany

Background

Low back pain continues to be responsible for more years lived with disability than any other disorder [1]. Multiple international studies attest to the massive health care and societal costs of low back pain [2]. Most of those affected have non-specific low back pain [3].

Low back pain can arise from the synovial facet joints [4]. Facet joint injury can occur from mechanical damage

due to compressive forces or extensive stretching; degenerative changes such as osteoarthritis and inflammatory processes including rheumatoid arthritis [5, 6]. Facet joints are richly innervated by the medial branches from the dorsal rami above and below each joint [7]. The proportion of people affected by low back pain for whom facet joint pain is a contributing factor is unclear. In an interventional pain management practice study the prevalence of chronic back pain being caused by facet joints was reported to be 31 % [8].

It is plausible that people whose low back pain is arising, at least in part, from facet joints is a sub-group for whom specific local treatment might be effective. The role of interventional procedures, such as intra-articular facet joint injections, in the management of low back pain is not clear. It is intra-articular injections for facet joint pain that are the focus of this review. Guidelines in both the UK and USA have not supported the use of intra-articular facet joint injections because of the absence of evidence to support their use [3, 9, 10]. Nevertheless, they are still widely used. Previous reviews of interventional procedures for low back pain have included multiple procedures and some have included both diagnostic and therapeutic injections. To aid our understanding of the possible role of intra-articular facet joint injection we have, in this review, focussed just on therapeutic intra-articular facet joint injections and have extended our interpretation to include consideration of the different populations recruited and differences in the comparator groups in our excluded studies.

Corticosteroids are established anti-inflammatory agents with demonstrable, short-term, benefits when injected intra-articularly to treat shoulder impingement syndrome or osteoarthritis of peripheral joints [11–15]. Intra-articular corticosteroid injections are beneficial in rheumatoid arthritis and have been shown to provide symptomatic relief for up to 3 months duration [16].

At a molecular level, corticosteroids may alter the transcription of pro-inflammatory genes [17]. The pain may originate from an inflammatory process occurring within the synovial joint or on the articular surfaces of the facet joints [18]. By reducing the levels of inflammation in or around the facet joint, there will be a reduction in the release of inflammatory mediators, which may be acting directly on the receptors or sensitising them to provoke a response.

With the success of corticosteroid injections in other joints and a firm knowledge of the mechanism of action of corticosteroids, it is reasonable to hypothesise that the same benefit could be delivered in another synovial joint, i.e. the facet joints. Furthermore, any symptom relief may facilitate adherence to physiotherapy or an exercise programme designed to improve lumbar range of movement and muscular stability [19].

Interpreting research data on treatment for facet joints needs to take into account how the exact research question being addressed impacts on study design and interpretation of the results. There are substantial challenges in arriving at a clinical diagnosis of probable facet joint pain; and hence, who should be considered for facet joint injections [20]. For a confirmed diagnosis, a positive diagnostic injection of local anaesthetic is required [21]. For studies of treatments for facet joint injections either clinical assessment or a positive diagnostic procedure can be used to define entry criteria. Intra-articular facet joint injections can be evaluated pragmatically by testing their effectiveness when they are compared with a conservative treatment (or no treatment). Alternatively they can be evaluated in more explanatory studies where they are compared to a placebo control or to a sham procedure.

We report a systematic review of randomised controlled trials of therapeutic intra-articular lumbar facet joint injections.

Specifically our objectives were:

1. To determine if facet joint injections with active drug are more effective in reducing back pain and back pain-related disability than a sham procedure or a placebo/inactive injection.
2. To determine if facet joint injections with active drug or placebo/inactive injection are more effective in reducing back pain and back pain-related disability than conservative treatment.

Methods

Types of studies

We prospectively registered our systematic review with the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42015018991) http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015018991.

We only included RCTs of therapeutic interventions; we excluded studies of diagnostic injections alone.

Types of participants

Male and female patients aged 18 or over reporting symptoms of acute (<6 weeks), sub-acute (6–12 weeks), or chronic (12 weeks or more) back pain.

Types of interventions

We only included studies on injections into or around the facet joints. Injections into other areas were excluded.

Sham procedures were defined as any procedure whereby the participant had believed a corticosteroid had been

injected into their facet joints. This may include inserting a needle into the facet joint, but not injecting a substance or using a device to replicate the sensation of a needle.

A placebo was defined as being any inert substance injected into or around the facet joint which may include saline.

Conservative therapy included the following interventions:

- Oral or topical medications.
- Corticosteroid injections other than into the facet joints.
- Physical therapies including exercise (supervised or unsupervised), acupuncture, and manual treatments (osteopathy and chiropractic).
- Psychological interventions including cognitive-behavioural therapy (CBT).

A sham facet joint injection and a corticosteroid injection delivered other than to the facet joints was considered to be a sham procedure. Injection of corticosteroid delivered other than to a facet joint without a sham facet joint injection was considered as conservative treatment.

Types of outcome measures

We considered trials reporting at least one of the following:

- Symptom relief based on pain.
- Back specific functional status (disability).

We included trials that included outcomes for short term (4 weeks), medium term (3 months) and long term (6 months or longer). Where there are other outcomes listed, we selected the closest matching to our categories.

We considered the following outcomes:

- Pain—measured by Visual Analogue Scale (VAS), Numerical Rating Scale (NRS) or McGill pain questionnaire or similar.
- Disability—measured by Oswestry disability index (ODI), Roland–Morris disability questionnaire (RMDQ), Million VAS disability score or Sickness Impact Profile (SIP) or similar.

We considered the following secondary outcomes:

- Adverse events.

Search methods for identification (electronic/other resources)

We used the search strategy developed by the Cochrane Back Review Group [22] and Chapter six ‘Searching for Studies’ of the Cochrane Handbook [23].

The following databases were searched for relevant studies:

- Medline
- EMBASE
- CINAHL
- CENTRAL
- Index to chiropractic literature

In addition, citation tracking of the studies retrieved by the search was conducted until no new studies were found. Ongoing trials were identified through the WHO International Clinical Trials Registry Platform (<http://www.who.int/ictpr/en/>) and ClinicalTrials.gov websites. Details of the search strategies are provided in the appendices (Appendix 1, available online as Supplemental Digital Content...).

Data collection and analyses

For each of the steps the two reviewers (RV, RB) independently selected studies, assessed the risk of bias, extracted data and resolved differences by consensus bringing in a third review author (HS or DE) when disagreements persisted.

Selection of studies

The two review authors screened the titles and abstracts after which the full text of potentially relevant studies were then retrieved for the final selection of eligible studies.

Data extraction and management

The two review authors independently extracted the data using standardised data extraction forms. The following information was collected:

- Study characteristics (aims of the study, study design, randomisation).
- Population characteristics—(patient population source or setting, study inclusion and exclusion criteria, duration of low back pain, diagnostic criteria, age, sex, country).
- Intervention characteristics—(description and types of corticosteroid, dose).
- Comparator characteristics—(description of comparator, duration, frequency).
- Outcome data—(pain intensity and disability at short term, medium term and long term).
- Number of participants assessed, number of dropouts.
- Statistical methods and results.
- Adverse events.

Fig. 1 Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow chart

Assessment of risk of bias in included studies

Two review authors independently assessed the risk of bias. Disagreements that could not be resolved were referred to a third review author (HS). The risk of bias assessment tool recommended by The Cochrane Collaboration [23, 24] and the Cochrane Back Review Group's updated method guidelines [22] were used. Studies were characterised as 'Low Risk', 'High Risk', or 'Unclear Risk' of bias for each of the criteria. A study with a low risk of bias was defined as having low risk on six or more of the items and no fatal flaws. A study was defined as having unclear risk of bias if one or more of the criteria did not have enough information.

Data synthesis

Heterogeneity between the included studies was explored by looking at the methodologies and outcomes being considered. We planned, where possible, to do meta-analyses. Heterogeneity in how the research questions were framed meant this was not possible. As such, we present a narrative synthesis of the available data.

Results

We identified 507 articles from electronic databases and an additional 24 from related systematic reviews. After removal of duplicates there were 393 unique articles which were screened for inclusion. We retrieved 42 full papers; 36 of these were excluded leaving six included studies. See Fig. 1. PRISMA flow diagram [25].

Included studies

We included six trials with a total of $N = 434$ participants (range 18–109 participants); Lilius [26], Carette [27], Mayer [28], Celik [29], Kawu [30] and Ribeiro [31].

The inclusion criteria were variable (Table 1). Two trials (Carette [27], Mayer [28]) included a diagnostic injection, into the facet joints, one trial, (Ribeiro [31]) used a combination of clinical and radiological assessment. The remaining three Lilius [26], Celik [29], and Kawu [30] used a clinical assessment only. The inclusion criteria fall under four broad headings these are: pain intensity or duration, physical tests, diagnostic tests, or more general criteria (see Table 1).

Table 1 Summary of included studies

No.	References and country	Participants	Inclusion/exclusion criteria	Intervention	Control
1.	Lilius et al. [26] Finland	61 women and 48 men (mean age 44 years, 19–64) IAC group, $n = 28$ PCC group, $n = 39$ IAS group (control) ($n = 42$)	Inclusion criteria: A negative straight leg raising test No improvement with previous analgesic and physiotherapy treatment	Intra-articular cortisone (IAC) group: 6 ml (30 mg) bupivacaine hydrochloride (Marcain) mixed with 2 ml (80 mg) methyl-prednisolone acetate was injected into each of the two facet joints Peri-capsular cortisone (PCC) group: 6 ml (30 mg) bupivacaine hydrochloride (Marcain) mixed with 2 ml (80 mg) methyl-prednisolone acetate was injected peri-capsularly around the two facet joints 20 mg (1 ml) methyl-prednisolone acetate in combination with 1 ml of isotonic saline	Intra-articular saline (IAS) group: 8 ml of physiological saline was injected into the two facet joints
2.	Carette et al. [27] Canada	Intervention $n = 49$ 51 % male, mean age 42.5 years Control $n = 48$ 58 % male, mean age 43 years	Inclusion criteria: Aged between 18 and 65 Had to have had a first or recurrent episode of low back pain, buttock pain or both for at least 6 months Pain could be intermittent or constant, unilateral or bilateral, radiating or non-radiating but had to be present Normal neurological examination results Exclusion criteria: Back pain without a mechanical cause (e.g. tumour, infection, spondylitis) Previous injections into facet joints or low back surgery Pregnancy Known allergy to local anaesthetic or radiological contrast agent		2 ml isotonic saline
3.	Mayer et al. [28] USA	Intervention $n = 36$ 75 % male, mean age 43.4 (± 8.5) years Control $n = 34$ 67.6 % male, mean age 46.2 (± 10.5) years	Inclusion criterion: Segmental rigidity on examination with maximum of 3 segments included (either unilateral or bilateral rigidity) Exclusion criteria: Declined injection as a treatment option More than 3 levels of segmental rigidity Failure to achieve insurance preauthorisation	Exercise plus 1 ml 2 % lidocaine, 1 ml 0.5 % bupivacaine including 1 ml of a depot corticosteroid preparation (unspecific)	Exercise only—twice a week in a facility and advised to do home stretching programme. Use facility 4–6 h, beginning once—twice a week and then ending final week with daily exercise

Table 1 continued

No.	References and country	Participants	Inclusion/exclusion criteria	Intervention	Control
4.	Celik et al. [29] Turkey	<p>Intervention $n = 40$ 13 males (32.5 %), 27 females (67.5 %) mean age 37.6 (± 9.2) years</p> <p>Control $n = 40$ 14 male (35 %), 26 females (65 %) mean age 34.9 (± 8.5) years</p>	<p>Inclusion criteria: Aged 20–60, male or female The patients suffered low back pain, but no extensions of pain to the legs Patient pain was exacerbated with hyperextension and alleviated by flexion Patient had maximally a 4-month history of pain</p> <p>Exclusion criteria: Patients with lumbar pathologies diagnosed by radiology such as lumbar herniated disc disease, spondylolisthesis, narrow spinal canal, scoliosis or other spinal deformities, fracture, mass lesions, etc. Patients with a history of major or radiologically demonstrable lumbar trauma Patients with radiologically demonstrated lumbar facet arthropathy, black disc or MODIC changes Patients with pathologies diagnosed by EMG such as mononeuropathies, polyneuropathies, and compression neuropathies or have a finding for root or nerve compression Patients with a history of previous lumbar surgery Patients with a metabolic bone disease Patients with a history of rheumatoid disease Patients with a serious systematic disease such as uncontrolled diabetes mellitus, chronic kidney failure, hypertension, chronic obstructive pulmonary disease, cardiac failure Patients with a neoplastic disease Patients with a psychiatric disease Patients have a sciatalgia, radiculopathy, neurological deficits Patients with an epileptic or severe neurological disease Child bearing women and suspicion of pregnancy Patients with a skin lesion on the lumbar area or systematic dermatological disease Patients with a venous failure on their legs Patients with a previously diagnosed surgical lumbar disease even if surgery was not performed</p>	<p>Bilateral L4/ and L5/S1 zygapophyseal joints blockage percutaneously with 22G spinal needle by prilocaine (skin preparation) 10 mg bupivacaine and 5 mg methyl-prednisolone</p>	<p>Diclofenac sodium 100 mg/day, thiocolchicoside 8 mg/day for 5 days and recommended bed rest for 4 days</p>

Table 1 continued

No.	References and country	Participants	Inclusion/exclusion criteria	Intervention	Control
5.	Kawu et al. [30] Nigeria	Intervention $n = 10$ 60 % male, mean age 42.3 (± 12.2) years Control $n = 8$ 60 % male, mean age 46.7 (± 10.4) years	Inclusion criteria: Chronic pain of more than 3 months' duration, not responding to conventional drugs Non-radicular low back pain Focal tenderness over the facet joint elicited by digital pressure MRI features of FJA Exclusion criteria: Radicular pain radiating below the knee MRI findings of nerve root compression Clinical or imaging of infection and neoplastic disease	0.5 ml of 0.25 % bupivacaine and 0.5 ml (20 mg) of methyl-prednisolone acetate were injected into the tender joints	Physiotherapy: patients had McKenzie regime $n = 29$ Intramuscular injections of 1 ml (20 mg) of triamcinolone hexacetonide and 1 ml of lidocaine on 6 surface points of the lumbar paravertebral musculature
6.	Ribeiro et al. [31] Brazil	Intervention $n = 31$ 80.6 % female, mean age 63.4 years Control $n = 29$ 82.8 % female, mean age 64.3 years	Inclusion criteria: Male and female patients aged between 18 and 80 years Continuous or intermittent low back pain for 3 months or longer Diagnosis of facet joint syndrome Pain upon baseline with an intensity of 4–8 on a 10-cm visual analogue scale (VAS) Informed consent Exclusion criteria: Known diagnosis of low back pain of an origin other than the facet joints Prior surgery on the spine Uncontrolled diabetes, systemic arterial hypertension, or glaucoma Diabetes with insulin use Fibromyalgia Changes in medications used for low back pain during the previous 2 months Allergy to the contrast medium Pregnancy or suspected pregnancy Current involvement in litigation	$n = 31$ L3–L4, L4–L5, L5–S1 injected bilaterally with 1 ml (20 mg) triamcinolone hexacetonide for total of 120 mg and 1 ml lidocaine	

Injection procedures and injectate

All six trials used different injection procedures with variations in the number of joints injected and whether they are injected unilaterally or bilaterally. Lilius [26] had two intervention groups who either had injections into the facet joints (intra-articular) or injections ‘around’ the facet joints (peri-capsular). These two groups were pooled for the final comparison.

The injectate used varied in volume and content. Three trials used a combination of bupivacaine hydrochloride (local anaesthetic) and methyl-prednisolone (corticosteroid) in various volumes and concentrations (Lilius [26], Celik [29], Kawu [30]). Carette used a combination of methyl-prednisolone and saline (no local anaesthetic). Mayer et al. used a combination of bupivacaine and a non-specified depot preparation corticosteroid. Ribeiro [31] used a combination of triamcinolone hexacetonide and lidocaine (Table 1).

Sham/placebo controls

Two trials Lilius [26] and Carette [27] used intra-articular saline as a placebo control, whilst Ribeiro [31] used active injections into para-spinal muscles as a sham control.

Conservative treatments

Three trials include a ‘conservative treatment’ as a control. One was a drug regime and at least 4 days bed rest (Celik [29]). In the other two trials the control treatment was a physical therapy one based on a McKenzie regime (Kawu [30]) and the other, facility based, exercises and advice to use stretching exercises at home (Mayer [28]). Two trials, Celik [29] and Kawu [30], used conservative treatment as an alternative to injections whilst Mayer [28] added injections to conservative treatment.

Two of the trials included a sample size calculation for their primary outcomes (Carette [27], Ribeiro [31]). Reason for incomplete follow-up was not reported in one study (Carette [27]), four studies had no loss at follow-up (Lilius [26], Mayer [28], Celik [29], Kawu [30]), one study (Ribeiro [31]) reported four dropouts, three missed follow-up and one, in the intervention group, died (not related to study).

Three trials reported adverse events. Lilius et al. [26], reported ‘few’ side effects but do not specify what they were. Carette et al. [27], report some localised pain near injection site. Ribeiro et al. [31] report adverse events, noting there were no significant differences between groups. These included; post-procedure pain ($n = 9$),

cutaneous hypochromia ($n = 1$), increase in blood glucose levels ($n = 5$), vaginal bleeding ($n = 3$), dizziness ($n = 3$) and nausea ($n = 3$). In addition, one control group patient had a serious adverse event; gastrointestinal bleeding, which required endoscopic therapy. They also note that one patient in the intervention group had a fall after a follow-up visit that caused an aggravation of the patient’s back pain.

Excluded studies

We excluded 36 studies which included Kennedy, 2013 and Hayes, 2006 which were excluded as there was only an abstract available [32, 33]. Contact was made with the lead author of the Kennedy paper who is in the process of submitting a manuscript. Brief details of the excluded studies are provided in the appendices (Appendix 2, available online as Supplemental Digital Content...).

Measures of outcome (i.e. pain and disability)

All six of the trials report on pain and disability outcomes (Table 2). All six of the trials used a visual analogue scale for pain, some of these are well defined with anchors described but others are less specific. Carette, also included the McGill pain questionnaire from which the ‘mean present pain intensity’ was taken as the variable of interest for this review.

Disability was measured with a variety of tools. Two trials included the Oswestry Disability Questionnaire with the first noting that they used a modified version and the second quotes they used the ‘Oswestry disability index’ (Celik [29], Kawu [30]). The four remaining trials all used different tools: Lilius et al. uses an undefined measure based on six physical actions; Carette et al. used a modified Sickness Impact Profile (SIP) measure with two of the original variables removed (eating and communicating); Mayer et al. used the Million VAS, a visual analogue scale based on 15 questions related to activities of daily living, and finally Ribeiro et al. used a Roland–Morris Disability Questionnaire (Table 2).

Length of follow-up

End of follow-up was between 5 and 7 weeks in Mayer, 3 months in Lilius, 24 weeks in Ribeiro and 6 months in Carette, Celik and Kawu (Table 2).

Quality assessment profiles

Figure 2 includes a quality assessment profile for each of the included trials. These are summarised below.

Table 2 Summary of outcome measures and there results

References	Outcome measures: pain	Outcome measures: disability	Measuring points	Outcomes: pain	Outcomes: disability
(a) Trials Injection verses sham control					
Lilius 1989 [26]	Pain Visual Analogue Scale (VAS) 0–100 mm (no anchors given)	Objective disability was graded one to three for the patient standing, walking, sitting, sitting with legs extended, climbing onto the examination table and dressing. A disability score, ranging from 6 to 18 was constructed by adding the six variables	Baseline then 1 h, 2 and 6 weeks post-treatment and for pain (only) at 3 months	Mean probability for <i>p</i> value differences between groups (combined cortisone vs. saline) = 0.3375 (mean and SD) pain score on a scale of 0–100 mm for all 109 patients Before injection = 49.2 (22.3) 1 h = 30.9 (25.6) 2 weeks = 35.8 (25.9) 6 weeks = 40.7 (25.7) 3 months = 43.3 (26.6) <i>p</i> < 0.0001	Mean probability for <i>p</i> value differences between groups (combined cortisone vs saline) = 0.1206 (mean and SD) Disability score ranging from 6 to 18 constructed from 6 variables scoring from 1 to 3: (standing, walking, sitting, sitting with legs extended, climbing onto examination table and dressing) Before injection = 10.3 (1.7) 1 h = 8.9 (2.3) 2 weeks = 9.1 (2.1) 6 weeks = 9.1 (1.9) <i>p</i> < 0.0001
Carette et al. [27]	Pain intensity: The McGill pain questionnaire (for this review we only include the mean present pain intensity variable) Also: A VAS, 0 = no pain to 10 = very severe pain	A modified Sickness Impact Profile. Eating and communication variables removed (by authors) as not related to LBP	Baseline then 1, 3 and 6 months post intervention	Mean present pain intensity, intervention, baseline = 2.7 Mean present pain intensity, control, baseline = 2.8 Mean present pain intensity, intervention, 1 month = 2.3, control = 2.6 Mean present pain intensity, intervention, 6 months = 2.1, control = 2.9 Baseline mean VAS, intervention, 6.3, control, 6.2 1 month mean VAS intervention, 4.5, control 4.7 Difference (95 % CI) = –0.2 (–1.1 to 0.8) 6 month mean VAS (0–10 cm scale) = 4.0 (methyl) = 5.0 (placebo) Difference (95 % CI) = –1.0 (–2.0 to –0.1)	Mean sickness impact profile, intervention, baseline, 11.4, control 13.4 Mean sickness impact profile intervention, 1 month 9.3 control 9.8 Difference (95 % CI) = –0.5 (–2.8 to 1.7) Mean sickness impact profile, intervention, 6 month, 7.8 control 10.8 Difference (95 % CI) = –3.0 (–6.2 to 0.2)

Table 2 continued

References	Outcome measures: pain	Outcome measures: disability	Measuring points	Outcomes: pain	Outcomes: disability
Ribeiro et al. [31]*	A 10 cm VAS, no anchors are given	Roland–Morris Disability Questionnaire	Baseline then 1, 4, 12 and 24 weeks after intervention	Intervention group mean (CI) VAS pain: T0 = 7.0 (6.5–7.4), T1 = 4.0 (3.0–5.0), T4 = 4.0 (3.0–5.0), T12 = 4.7 (3.5–5.7) T24 = 5.3 (4.4–6.1), ($p < 0.001$) Control group mean (CI) VAS pain: T0 = 6.8, (6.2–7.3), T1 = 4.0 (3.0–4.9), T4 = 3.6 (2.3–4.7), T12 = 6.1 (5.0–7.0), T24 = 5.8 (4.5–6.9), ($p < 0.001$) No differences between the two groups	Intervention group mean (CI) Roland–Morris disability questionnaire: T0 = 15 (13.1–16.8), T1 = 11.5 (9.1–13.7), T4 = 10.2 (7.8–12.4), T12 = 10.6 (8.2–12.9), T24 = 10.9 (8.2–13.5), ($p < 0.001$) Control group mean (CI) Roland–Morris disability questionnaire: T0 = 16.4 (14.2–18.6), T1 = 13.4 (10.6–16.2), T4 = 12.2 (9.7–14.6), T12 = 14.7 (12.3–16.9), T24 = 13.4 (10.8–15.9), ($p < 0.001$) No differences between two groups over time. However analysis at each time point showed statistical difference at week 12 ($p = 0.01$)
(b) Injection versus conservative treatment control					
Mayer et al. [28]*	Pain intensity: A 10-cm line VAS, 0 = no pain to 10 = most severe pain	The Million VAS, represents the answers to 15 items on how pain affects activities of daily living, with a range from ‘no disability (0) to ‘most disability’ (150)	Baseline to follow-up 5–7 weeks	Intervention group pain intensity: Pre 6.3 (± 1.5), post 5.4 (± 1.6). $p \leq 0.003$, a 53 % Control group Pre 6.7 (± 1.8), post 5.9, (± 2.1). $p \leq 0.004$, a 50 % improvement Between groups differences not significant	Intervention group Million VAS: Pre 99.7 (± 16.7), post 85.6 (± 21.5). $p \leq 0.001$, a 72 % improvement Control group Pre 100 (± 29.2), post 92.2 (± 25.1). $p \leq 0.003$, a 68 % improvement Between groups differences not significant
Celik et al. [29]	Noted as a VAS but no clear definition	Modified Oswestry low back pain disability questionnaire (ODQ)	Baseline then first and fifth days and first, third and sixth month	Intervention group: VAS pre-treatment = 8. Immediately after = 2. 1st month = 1. 3rd month = 5. 6th month = 2 Control group: VAS pre-treatment = 7. Immediately after = 3. 1st month = 2. 3rd month = 4. 6th month = 5 Decrease in VAS scores in post-treatment, 1st, 3rd and 6th month were not statistically significant ($p > 0.005$) Between-group differences not reported	Intervention group: ODQ pre-treatment = 23. Immediately after = 5. 1st month = 5. 3rd month = 11. 6 months = 3 Control group: ODQ pre-treatment = 21. Immediately after = 9. 1st month = 4. 3rd month = 7. 6th month = 11 Reduction in ODQ scores in intervention group was greater than in control group ($p < 0.005$) Between-group differences not reported

Table 2 continued

References	Outcome measures: pain	Outcome measures: disability	Measuring points	Outcomes: pain	Outcomes: disability
Kawu et al. [30]	Noted as a VAS but no clear definition	Oswestry disability index	Baseline then 6 weeks, 3 and 6 months	<p>Intervention group VAS pain:</p> <p>Male: pre-intervention = 7.8 ± 1.9, 6-week score = 5.9 ± 2.1, 3-month score = 4.5 ± 1.3 6-month score = 4.1 ± 1.7</p> <p>Females: pre-intervention = 7.2 ± 1.6, 6-week score = 5.1 ± 2.1, 3-month score = 4.1 ± 1.5, 6-month score = 3.9 ± 1.2</p> <p>Control group VAS:</p> <p>Male: Pre-intervention = 7.4 ± 2.1, 6-week score = 6.8 ± 1.9, 3-month score = 5.8 ± 1.6, 6-month score = 5.2 ± 1.3</p> <p>Female: Pre-intervention = 7.0 ± 2.3, 6-week score = 6.4 ± 1.5, 3-month score = 5.2 ± 1.4, 6-month score = 4.8 ± 1.9</p> <p>Post intervention mean VAS significantly lower in intervention group ($p = 0.032$)</p>	<p>Intervention group ODI:</p> <p>Male: Pre-intervention = 58.6 ± 6.8, 6-week score = 49.7 ± 6.2, 3-month score = 42.3 ± 5.5, 6-month score = 39.6 ± 4.9</p> <p>Females: Pre-intervention = 52.3 ± 9.2, 6-week score = 47.0 ± 7.1, 3-month score = 38.9 ± 6.8 6-month score = 37.1 ± 5.2</p> <p>Control group ODI:</p> <p>Male: Pre-intervention = 59.0 ± 8.6, 6-week score = 55.3 ± 5.4, 3-month score = 53.7 ± 7.2, 6-month score = 51.8 ± 6.3</p> <p>Female: Pre-intervention = 56.3 ± 8.9, 6-week score = 53.4 ± 7.1, 3-month score = 38.7 ± 6.3, 6-month score = 37.1 ± 4.9</p> <p>FJI group fared consistently better with a low mean score against the mean score against the mean score of the physiotherapy group. No direct information specifically reported for the ODI except graph showing ODI against time</p>

* Trials including a diagnostic block injection

Fig. 2 Risk of bias assessments for included trials

	Lilius 1989	Carette 1991	Mayer 2004	Celik 2011	Kawu 2011	Ribeiro 2013
Random Sequence Generation	?	+	-	?	?	+
Allocation concealment	?	?	-	?	?	+
Blinding of participants	?	+	-	-	-	+
Blinding of personnel/care providers	?	+	-	-	-	-
Blinding of outcomes assessors	+	+	-	-	-	+
Incomplete outcome data	+	+	+	+	+	+
Selective outcome reporting	+	+	+	+	+	+
Group similarity at baseline	+	+	+	+	+	+
Co-interventions	+	?	?	+	?	-
Compliance	+	+	+	?	?	+
Intention-to-treat analysis	+	-	+	?	+	+
Timing of outcome assessments	+	+	?	+	+	+
Other bias	+	+	+	?	+	+
Key: ? Unclear risk of bias. + Low risk of bias. - High risk of bias.						

Allocation (selection bias)

There was generally low-risk allocation bias across all studies with concealment maintained. However, there were two studies from which it was not possible to determine risk of allocation bias as there was no description of the process. One study (Mayer) was at high risk of allocation bias as patients were allocated to the two groups in an alternating manner (see Fig. 2).

Blinding (performance bias and detection bias)

One study (Lilius) was unclear on its method of blinding and whether participants were truly blinded to what they were receiving.

In Carette's study, the participants were blinded as to which treatment they were receiving with the syringe covered in tin foil for both control and intervention. The care providers and assessors were also blinded.

Celik et al. had high risk of blinding bias due to the control being exercise or physiotherapy, the participants could not be blinded to the process.

Ribeiro was partially blinded with the participants; however, the care providers were not blinded as they were injecting the control and treatment in different anatomical sites.

Incomplete outcome data (attrition bias)

In two studies (Lilius and Carette) there were patients who did not attend the follow-up examination post-treatment; however, this was deemed to be insignificant to the outcomes drawn by the paper as they were from both the control and intervention groups. Similarly, in another study

(Ribeiro), there was low risk of attrition bias as equal numbers were lost from the control and intervention groups. Celik et al. studies were low risk as no patients left the study.

Selective reporting (reporting bias)

These are generally low risk across the studies with the pre-specified set of outcomes being reported.

Effects of interventions

Here we present the outcomes of the trials split into two categories, which are:

- Injection versus sham control.
- Injection versus conservative treatment control.

Those including a diagnostic injection will be highlighted. Understanding how differences in participant selection, and the comparators used in these trials is critical to understanding how the results might be interpreted and where data pooling might be possible. We have sought to clarify the differences and similarities in Fig. 3.

Below we summarise the outcome findings from the trials details can be found in Table 2.

Injection versus sham control (pain and disability outcomes)

Three trials have an injection versus a sham injection control (Lilius [26], Carette [27], Ribeiro [31]) with one (Carette [27]) using a diagnostic injection before randomisation (Table 2a). In the Carette trial 190 patients were given the diagnostic injection (lidocaine), 110

Fig. 3 Summary of designs of included studies. Entry criteria; *clinical* clinical assessment only, *radiographic* clinical plus radiological change, *block* clinical plus positive diagnostic block, *acute* pain <3 months, *chronic* pain more than 3 months: interventions, *LA* local anaesthetic, *NSAID* non-steroidal anti-inflammatory drugs, *McKenzie* McKenzie exercise technique

patients met the inclusion criterion of a 50 % or more reduction in pain, two of these had no recurrence of pain and seven chose not to participate. Therefore, 101 patients entered the randomised phase (intervention, $n = 51$, placebo, $n = 50$). Four patients, two in each arm, were later excluded from analysis for not meeting inclusion criteria.

None of these trials report significant differences in pain or disability between groups at their pre-specified primary outcome. Carette [27] reports significant between-group differences in the visual analogue pain score (mean difference -1.0 , 95 % CI -2.0 to -0.1) and the sickness impact profile (physical dimension) (mean difference -3.0 , 95 % CI -6.2 to 0.2) at final follow-up (6 months) [27]. Ribeiro report statistically significant differences in role physical sub-scale of SF-36 over 24 weeks ($p = 0.023$), 'improvement percentage' at 1 and 24 weeks ($p = 0.03$

and $p = 0.04$), pain improvement at week one ($p = 0.029$), Diclofenac use ($p = 0.04$), and Roland-Morris Disability score at 12 weeks ($p = 0.01$) [31].

Injection versus conservative treatment control (pain and disability outcomes)

Three trials have injection versus a conservative treatment (Mayer [28], Celik [29], Kawu [30]) with one (Mayer [28]) using a diagnostic injection (see Table 2b). One trial (Mayer [28]) reports no significant differences between groups for either pain or disability at follow-up (5–7 weeks). The results in the Kawu trial are presented within group, but they do state that there was a significant between-group improvements in pain (intervention, males, mean 4.1 ± 1.7 , females 3.9 ± 1.2 and control males

5.2 ± 1.3 , females 4.8 ± 1.9 , $p = 0.032$) at 6-month follow-up. For disability outcomes they report a significant improvement over time ($p = 0.013$) [30]. Celik [29] only report within-group data; there are no between-group results reported (Table 2).

Discussion

Our systematic review revealed that there were few trials of intra-articular facet joint injections. That no two trials have tested similar hypotheses means it is difficult to draw any clinically useful conclusions.

There is a wide range in the quality of the six trials reported here. Only two, (Carette [27], Ribeiro [31]) reported a sample size calculation, and had clear information on randomisation and only one of these provided information about allocation-concealment [31].

There is no consistent pattern of benefit across trials. Some show levels of improvement whilst others find none. Indeed, patients improve with and without the intervention treatment. In the Lilius study, they found there was improvement in pain and disability across all three intervention groups [26]. Similarly, in the Ribeiro trial both treatments are found to be equally effective with only a slightly larger improvement following intra-articular steroids over intramuscular injections in some secondary outcomes; but without a consistent pattern. Both groups were found to have improvement with regard to functional status; however, the difference between them was not statistically significant until week 12. The co-intervention intake was significantly different between the two groups with diclofenac intake reduced in the experimental group [31].

Mayer suggests that corticosteroid injections in conjunction with supervised stretching exercises may improve pain or disability outcomes rather than exercise alone. However, they concluded that facet joint injections do not explain the improved pain and disability outcomes observed in the control and treatment groups as the pre- and post-trial measures were comparable and therefore could not be attributed to the pharmacological profile of the cortisone taking effect. Even though the range of lumbar movement was observed to be significantly improved in the treatment group. The study also stated possible bias due to the difference in segmental rigidity of participants between both groups despite randomisation, but due to the range of movements being opposite in both groups, they disregarded this as a potential source of bias [28].

The Kawu trial does report a positive significant result for both pain and disability outcomes at 6 months [30]. The control, conservative treatment, in this trial was physiotherapy (McKenzie technique) this technique encourages extension of the back. There is now a growing body of

evidence that this will just make the pain worse for those with chronic low back pain particularly those with facet joint pain. Thus it maybe that the lack of improvement in pain and disability outcomes in the control group was due to exacerbation of the patients back pain problems by the exercises given [34].

Overall completeness of evidence in terms of applicability, from the current evidence, does not support the use of intra-articular facet joint injections. However, as statistically significant between-group differences are reported in some secondary outcomes (all favouring intervention) in some of the studies there is merit in further investigating their potential effectiveness.

In the majority of studies presented in this review, no adverse events or side effects associated with the treatments were reported. Transient symptoms such as increased low back discomfort were noted though most trials were small and not designed to evaluate adverse events, so no clear conclusion can be drawn regarding the risks of facet joint injections. It is important that future trials record any adverse events while using these procedures in order to appropriately weigh any benefits against potential risks.

It is possible that in searching studies for this review, relevant but unpublished trials may have been missed, which are often likely to be small studies without positive results, leading to publication bias. However, because the majority of published trials was small and did not show a positive effect, publication bias does not seem to be a big problem in this review.

Due to the study selection criterion used, including only trials of intra-articular facet joint injections, this review included fewer studies than similar reviews [9, 35]. Many excluded RCTs used different types of injection therapy and denervation procedures. However, the main conclusions of our review appear to be similar to recent systematic reviews, which generally report a paucity of high-quality RCTs on injection therapy for lower back pain and insufficient evidence to support their use.

Conclusions

Facet joint injections are commonly used; however, there is insufficient high-quality evidence to support their usage over placebo/sham-controlled procedures or conservative therapy for lower back pain. Further investigations are required to prove their efficacy in targeting lower back pain, which is attributed to facet joints and this must be balanced against any potential adverse events as a result of the injections.

Further randomised controlled trials of higher methodological standard comparing facet joint injection with a

sham/placebo control or conservative treatment are needed from which to base any conclusion on the effectiveness of facet joints in improving pain and disability outcomes.

Acknowledgments This project benefited from facilities funded through Birmingham Science City Translational Medicine Clinical Research and Infrastructure Trials Platform, with support from Advantage West Midlands. The team wish to acknowledge the NIHR (HTA Project: 11/31/01—Facet Feasibility) whilst not funding this project the grant is covering the salary of one of the team (DE).

Compliance with ethical standards

Conflict of interest MU is principal investigator and HS is a co-investigator for a trial exploring the feasibility on doing a randomised controlled trial testing the addition of intra-articular facet joint injections to best usual care (HTA Project: 11/31/01—Facet Feasibility). DE is also working on this trial as a researcher. The other authors report no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 380(9859):2163–2196. doi:10.1016/S0140-6736(12)61729-2
- Dagenais S, Caro J, Haldeman S (2007) A systematic review of low back pain cost of illness studies in the United States and internationally. *Spine J* 8(1):8–20. doi:10.1016/j.spinee.2007.10.005
- NICE (2009) Low back pain: early management of persistent non-specific low back pain. National Institute for Health and Care Excellence. <https://www.nice.org.uk/guidance/cg88/resources/guidance-low-back-pain-pdf>. Accessed 08 Aug 2015
- Manchikanti L, Singh V (2002) Review of chronic low back pain of facet joint origin. *Pain Physician* 5(1):83–101
- Lewinnek GE, Warfield CA (1986) Facet joint degeneration as a cause of low back pain. *Clin Orthop* 213:216–222
- Dreyfuss PH, Dreyer SJ, Herring SA (1995) Lumbar zygapophysial (facet) joint injections. *Spine* 20(18):2040–2047
- Bogduk N, Wilson AS, Tynan W (1982) The human lumbar dorsal rami. *J Anat* 134(Pt 2):383–397
- Manchikanti L, Boswell MV, Singh V, Pampati V, Damron KS, Beyer CD (2004) Prevalence of facet joint pain in chronic spinal pain of cervical, thoracic, and lumbar regions. *BMC Musculoskelet Disord* 5(15):15. doi:10.1186/1471-2474-5-15
- Chou R, Loeser JD, Owens DK, Rosenquist RW, Atlas SJ, Baisden J, Carragee EJ, Grabis M, Murphy DR, Resnick DK, Stanos SP, Shaffer WO, Wall EM (2009) Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. *Spine* 34(10):1066–1077. doi:10.1097/BRS.0b013e3181a1390d
- Manchikanti L, Abdi S, Atluri S, Benyamin RM, Boswell MV, Buenaventura RM, Bryce DA, Burks PA, Caraway DL, Calodney AK et al (2013) An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations. *Pain Physician* 16(2 Suppl):S49–S283
- Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G (2006) Intraarticular corticosteroid for treatment of osteoarthritis of the knee. *Cochrane Database Syst Rev* 2:CD005328
- Buchbinder R, Green S, Youd JM (2003) Corticosteroid injections for shoulder pain. *Cochrane Database Syst Rev* 1:CD004016
- Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, Hauselmann HJ, Herrero-Beaumont G, Jordan K, Kaklamanis P, Leeb B, Lequesne M, Lohmander S, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Swoboda B, Varatojo R, Verbruggen G, Zimmermann-Gorska I, Dougados M, Therapeutics ESCfCSI (2005) EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis* 64(5):669–681
- Machado E, Bonotto D, Cunali PA (2013) Intra-articular injections with corticosteroids and sodium hyaluronate for treating temporomandibular joint disorders: a systematic review. *Dental Press J Orthod* 18(5):128–133
- Colen S, Geervliet P, Haverkamp D, Van Den Bekerom MP (2014) Intra-articular infiltration therapy for patients with glenohumeral osteoarthritis: a systematic review of the literature. *Int J Shoulder Surg* 8(4):114–121. doi:10.4103/0973-6042.145252
- van Vliet-Daskalopoulou E, Jentjens T, Scheffer RT (1987) Intra-articular rimexolone in the rheumatoid knee: a placebo-controlled, double-blind, multicentre trial of three doses. *Br J Rheumatol* 26(6):450–453
- Barnes PJ, Adcock I (1993) Anti-inflammatory actions of steroids: molecular mechanisms. *Trends Pharmacol Sci* 14(12):436–441
- Kidd BL, Morris VH, Urban L (1996) Pathophysiology of joint pain. *Ann Rheum Dis* 55(5):276–283
- Jack K, McLean SM, Moffett JK, Gardiner E (2010) Barriers to treatment adherence in physiotherapy outpatient clinics: a systematic review. *Man Ther* 15(3):220–228. doi:10.1016/j.math.2009.12.004
- Mars T, Ellard D, Antrobus J, Cairns M, Underwood M, Haywood K, Keohane S, Sandhu H, Griffiths F (2015) Intraarticular facet injections for low back pain: design considerations, consensus methodology to develop the protocol for a randomized controlled trial. *Pain Physician* 18(5):473–493
- Sehgal N, Dunbar EE, Shah RV, Colson J (2007) Systematic review of diagnostic utility of facet (zygapophysial) joint injections in chronic spinal pain: an update. *Pain Physician* 10(1):213–228
- Furlan AD, Pennick V, Bombardier C, van Tulder M, Editorial Board CBRG (2009) 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. *Spine* 34(18):1929–1941. doi:10.1097/BRS.0b013e3181b1c99f
- Higgins JPT GSe (2011) The Cochrane collaboration, 2011. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.10. Available from www.cochrane-handbook.org. Accessed March 2011
- Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G (2011) The Cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 343:d5928. doi:10.1136/bmj.d5928

25. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 339:b2535. doi:[10.1136/bmj.b2535](https://doi.org/10.1136/bmj.b2535)
26. Lilius G, Laasonen EM, Myllynen P, Harilainen A, Gronlund G (1989) Lumbar facet joint syndrome: a randomised clinical trial. *J Bone Joint Surg Br* 71(4):681–684
27. Carrette S, Marcoux S, Truchon R, Grondin C, Gagnon J, Allard Y, Latulippe M (1991) A controlled trial of corticosteroid injections into facet joints for chronic low back pain. *N Engl J Med* 325(14):1002–1007
28. Mayer TG, Gatchel RJ, Keeley J, McGeary D, Dersh J, Anagnostis C (2004) A randomized clinical trial of treatment for lumbar segmental rigidity. *Spine* 29(20):2199–2205
29. Celik B, Er U, Simsek S, Altug T, Bavbek M (2011) Effectiveness of lumbar zygapophysial joint blockage for low back pain. *Turk Neurosurg* 21(4):467–470
30. Kawu AA, Olawepo A, Salami AO (2011) Facet joints infiltration: a viable alternative treatment to physiotherapy in patients with low back pain due to facet joint arthropathy. *Niger J Clin Pract* 14(2):219–222. doi:[10.4103/1119-3077.84021](https://doi.org/10.4103/1119-3077.84021)
31. Ribeiro LH, Furtado RN, Konai MS, Andreo AB, Rosenfeld A, Natour J (2013) Effect of facet joint injection versus systemic steroids in low back pain: a randomized controlled trial. *Spine* 38(23):1995–2002. doi:[10.1097/BRS.0b013e3182a76df1](https://doi.org/10.1097/BRS.0b013e3182a76df1)
32. Hayes (2006) Facet blocks for chronic back pain (Structured abstract). HAYES, Inc. <http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?AccessionNumber=32006001570&UserID=0>. Accessed 04 June 2015
33. Kennedy DJ, Stout AA, Conrad B, Smuck M (2013) A randomized, double-blind, placebo-controlled, prospective study of intraarticular lumbar zygapophysial joint corticosteroid injection(s) as treatment of chronic low back pain in a selected population. *Phys Med Rehabil* 5(9):S286. doi:[10.1016/j.pmrj.2013.08.508](https://doi.org/10.1016/j.pmrj.2013.08.508)
34. Machado LA, de Souza M, Ferreira PH, Ferreira ML (2006) The McKenzie method for low back pain: a systematic review of the literature with a meta-analysis approach. *Spine* 31(9):E254–E262. doi:[10.1097/01.brs.0000214884.18502.93](https://doi.org/10.1097/01.brs.0000214884.18502.93)
35. Staal JB, de Bie RA, de Vet HC, Hildebrandt J, Nelemans P (2009) Injection therapy for subacute and chronic low back pain: an updated Cochrane review. *Spine* 34(1):49–59